On April 2, 2026, the U.S. Environmental Protection Agency (EPA) released the Draft Sixth Contaminant Candidate List (CCL 6) under the Safe Drinking Water Act. As with prior cycles, the list does not establish regulation or compliance requirements. It signals where the science, monitoring and regulatory attention are heading.
That distinction matters
CCL 6 introduces 75 individual chemical contaminants, 4 contaminant groups and 9 microbial contaminants, including the first-time inclusion of microplastics and pharmaceuticals. These additions reflect increased interest around emerging contaminants but also highlight a familiar challenge. The science is still developing and regulatory pathways are not yet defined.
For the industry, this creates a period of ambiguity. There is no immediate compliance obligation, but there is increasing scrutiny. Inclusion on the CCL often precedes expanded monitoring, stakeholder questions and pressure from regulators, customers and investors. In that environment, the quality of underlying data becomes as important as the data itself.
Group listings raise questions, not answers
The inclusion of contaminant groups such as PFAS, microplastics and pharmaceuticals reflects EPA’s recognition that exposure potential may exist across broad classes of compounds. At the same time, grouping underscores scientific uncertainty.
History offers a clear parallel. Hydrocarbons have been studied for decades, yet federal regulation has never applied to the class as a whole. Instead, only a limited number of compounds, such as benzene, toluene, ethylbenzene and xylenes (BTEX) and select polyaromatic hydrocarbons (PAHs), were ultimately regulated based on consistent evidence of occurrence, toxicity and treatability.
The same constraints apply today. Analytical variability, differences in environmental behavior and evolving toxicological research make class-wide regulation unlikely in the near term. Instead, the path forward will be iterative, data-driven and selective.
Early-stage regulation requires a broader science-forward view
CCL inclusion moves contaminants into the regulatory pipeline, where they may be evaluated through occurrence monitoring, health assessments and ultimately Regulatory Determinations (determination by the EPA if regulation is warranted. At each step, decisions rely on data that is often incomplete, variable or generated across multiple laboratories and methods.
In a CCL context, organizations need a science-forward strategy that connects sampling methodologies, analytical methods, toxicology, chemistry, ecology, receptors, migration pathways, and treatment feasibility. The challenge is not simply confirming whether a dataset is technically correct. It is understanding what the data actually means when the regulatory path is still taking shape.
For emerging chemicals of concern, that broader perspective matters. EPA’s own framing for CCL 6 emphasizes prioritizing research and filling data gaps, particularly for contaminant groups such as microplastics and pharmaceuticals where occurrence, exposure and health implications are still being defined. Organizations that can interpret uncertain data in a defensible scientific context will be better prepared than those focused only on a narrow pass-fail view of laboratory outputs.
Why science-forward support cannot be a downstream step
CCL 6 reinforces a broader reality. Defensible decisions come from more than a final quality check.
As agencies, utilities and site owners continue to engage with emerging contaminants, they will need support that goes beyond reviewing qualifiers or reconciling laboratory discrepancies. They will need to understand whether a method is fit for purpose, how results align with toxicological relevance, what the data may mean for exposure, and whether treatment options are realistic as expectations evolve.
That is where a science-forward approach has more strategic value. It helps clients make informed decisions even when the path forward is uncertain, and it builds a stronger foundation for monitoring strategies, risk communication and future regulatory engagement.
The starting point, not the endpoint
CCL 6 does not create limits, require monitoring or mandate treatment changes. But it does mark the beginning of the next cycle of scientific evaluation and regulatory consideration.
Historically, only a small fraction of CCL contaminants progress to enforceable standards. The ones that do are supported by years of data, analysis and validation.
For industry, the takeaway is straightforward. Early engagement matters. Not only in tracking EPA activity, but in building science-forward strategies that can stand up to regulatory scrutiny as emerging chemicals move from concern to evaluation. In the early stages of regulation, confidence does not come from data alone. It comes from understanding the science well enough to act before the rules are written.